Johnson & Johnson 67953964SCH1001
About the Study
This study is for adults with schizophrenia looking for an adjunctive treatment method.
The purpose of this study is to assess the safety, tolerability, and efficacy of Aticaprant as an adjunctive treatment for adults living with schizophrenia. All participants will continue their current treatment with permitted background antipsychotic medications (oral or long-acting injectable) at the same dose, without change, taken approximately around the same time of the day (if oral) as prior to entering the study.
This study is sponsored by Johnson & Johnson.
Eligibility
You may be eligible to participate in this study if you:
are between the ages of 18-55 years old
are clinically stable living with schizophrenia symptoms for at least one year
are on a stable dose of one of the following atypical antipsychotic medications:
asenapine, iloperidone, lumateperone, lurasidone, olanzapine, paliperidone, quetiapine, risperidone, or ziprasidone
have a trusted caregiver/informant such as a family member, social worker, or case worker, who can reliably and willingly participate as a study informant (either in person or via telephone)
If chosen for this study, you will be compensated for every study visit that you complete and we can provide transportation if needed.
If you are interested in participating in this clinical trial, please call our friendly staff at 773-989-8313 ext. 116 today. You can also fill out the contact form below.